Recommended Stack
Richard
An educational peptide stack generated from the Stack Quiz.
Your Stack Summary
46-year-old male with 20 years training experience, currently cutting with mixed moderate-intensity training 5x/week. Priority is muscle gain with conservative risk tolerance and low side-effect tolerance. Has some peptide experience with CJC1295/Ipamorelin and BPC-157/TB-500. Family history of cancer requires caution around growth-promoting agents. Prefers injectable, nasal, or oral delivery with daily frequency tolerance and £100-300 monthly budget.
Examorelin
Muscle gainSynthetic hexapeptide that acts as a ghrelin mimetic, binding to the growth hormone secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus to stimulate pulsatile growth hormone release, which may support muscle protein synthesis and body composition during a cut.
Somatotropin
Muscle gainBinds to growth hormone receptors on target cells, activating the JAK2-STAT5 signaling pathway, stimulating IGF-1 production in the liver and peripheral tissues, promoting anabolic processes including protein synthesis and lipolysis.
Lonapegsomatropin
Muscle gainLong-acting PEGylated prodrug of somatropin that releases active growth hormone over time, binding to growth hormone receptors to stimulate IGF-1 production and promote linear growth and anabolic metabolic effects with less frequent dosing.
Safety Notes
- Family history of cancer requires heightened caution with growth hormone-related peptides; active malignancy is a contraindication for somatotropin, lonapegsomatropin, and examorelin per catalog data
- Somatotropin and lonapegsomatropin are prescription-only medications with significant adverse effect profiles including fluid retention, insulin resistance, and intracranial hypertension; examorelin is research-grade with less regulatory oversight
- Growth hormone axis stimulation may cause water retention, joint pain, and potential insulin resistance—particularly relevant during a cutting phase
- These examples are for educational discussion with a qualified clinician only; none should be initiated without medical supervision, proper screening, and monitoring of IGF-1 levels
- Given conservative risk tolerance and family cancer history, prioritizing examorelin (nasal, research-grade) over prescription growth hormones may align better with harm reduction, though all options require clinician evaluation
- Regular monitoring of fasting glucose, IGF-1, and cancer screening adherence is essential if any growth hormone axis modulation is pursued